Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (4676)	7/1/1998 2:37:00 AM
From: billkirn	Respond to of 6136

I can't help believe Peter and the Agouron Team have the ability to select the best possible candidates and have assembled a great team to file and get drug approval through the FDA, fast. It seems to me that the additional investment and commitment to the HIV front could mean the cancer front may not have as much potential. With the sales force, the FDA approval team, Viracept, great new emerging drug candidates for the HIV front and potential cancer products, we are in good hands. The ride will be good and long term.. Bill

To: scaram(o)uche who wrote (4676)	7/1/1998 9:25:00 AM
From: Peter Singleton	Read Replies (3) \| Respond to of 6136

I did an altavista search KNI-272 (Japan Energy's 1st generation PI). There's a fair amount of information (albeit sketchy) on the compound. I don't have time this morning to post it, but a quick scan indicates the compound was developed around the time the currently marketed PIs were, showed some modest promise, but in the early clinical work it developed resistance in the same way as the other PIs, and wasn't as potent. Japan Energy and their collaborators went back to the drawing board, and AGPH has licensed their follow-on compound ..